Mometason Furoát Cipla (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors in airway cells, altering gene transcription to suppress inflammatory cytokines, reduce leukocyte infiltration, and limit mucus production. This anti‑inflammatory action decreases swelling and hyper‑responsiveness of the airways, leading to better airflow and symptom control.

The specific dose and frequency of Mometason Furoát Cipla are determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Healthcare professionals tailor the inhalation regimen to achieve optimal control while minimizing potential side effects.

The safety of Mometason Furoát Cipla in pregnancy and lactation has not been definitively established. Physicians should weigh the potential benefits against possible risks and consider alternative treatments when appropriate. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any cold‑chain needs), and assists with import documentation.

Mometason Furoát Cipla contains mometasone furoate, a potent glucocorticoid with high local anti‑inflammatory activity and low systemic absorption. Compared with agents such as budesonide or fluticasone, it offers similar efficacy for asthma and COPD control, but dosing frequency and device compatibility may differ, influencing patient preference and adherence.

Store the inhaler at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the mouthpiece remains clean. Do not expose the product to extreme heat or freeze it, as this could affect the formulation.

The medication is delivered via a metered‑dose inhaler or dry‑powder inhaler, as specified by the product label. Patients should inhale a full dose after a slow, deep breath, hold their breath for a few seconds, and then exhale slowly. Rinsing the mouth after each use helps reduce the risk of oral thrush.

Serious risks include paradoxical bronchospasm, severe allergic reactions (anaphylaxis), adrenal suppression with high‑dose or prolonged use, and rare systemic effects such as osteoporosis or cataract formation. Patients should be educated to recognize early signs of these events and seek medical attention promptly.

Patients with known hypersensitivity to mometasone furoate, other corticosteroids, or any excipients in the inhaler should avoid its use. Caution is also advised for individuals with active, untreated infections, uncontrolled diabetes, or a history of severe osteoporosis, and the decision should be made by a qualified healthcare professional.